Four Product Development Candidates
| Product | Indications |
|---|---|
| TCEL-100 | Solid tumors |
| TCEL-200 | Solid tumors |
| TT-300 | Pancreatic, Colorectal, Lung |
| TT-400 | Solid tumors |
| Preclinical | Phase I | Phase II |
|---|---|---|
Product Development Candidates
TCEL-100
TCEL-100 is a preclinical candidate. T-CEL-100 is an adoptive cell therapy product consisting of T-cells expanded from tumor infiltrating lymphocytes. The T-cells were selected based on the profile of selection markers indicative of potential for tumor reactivity. T-CEL-100 is polyclonal, meaning it targets multiple neoantigens expressed by the tumors.
TCEL-200
TCEL-200 is a preclinical candidate. TCEL-200 is an adoptive cell therapy product consisting of T-cells expanded from tumor infiltrating lymphocytes. The T-cells were selected based on the profile of selection markers indicative of potential for tumor reactivity. Further, the T-cells selected for expansion were assessed for their ability to recognize and bind to peptides expressed by the patient’s immune system cells, ex-vivo. TCEL-200 is polyclonal, meaning it potentially targets multiple neoantigens expressed by the tumors.
TT-300
TT-300 is a preclinical candidate. TT-300 is an adoptive cell therapy product consisting of T-cells engineered to express the receptor to a neoantigen, in this case a common driver mutation. TT-300 will be evaluated in patients harboring the target mutation.
TT-400
TT-400 is a preclinical candidate. TT-400 is an adoptive cell therapy product consisting of T-cells engineered to express the receptor to a neoantigen, in this case a common driver mutation. TT-400 will be evaluated in patients harboring the targeted mutations.